Wilex Shares Plunge; Rencarex Disappoints in Phase III Study
By Cormac Sheridan
Tuesday, October 16, 2012
Shares in Wilex AG plunged 60 percent just before the markets closed in Frankfurt, Germany, Tuesday, on news that a protracted Phase III trial of Rencarex (girentuximab) failed to meet the primary endpoint of disease-free survival in patients with clear cell renal carcinoma (ccRCC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.